by barry101 | Mar 19, 2024 | Press Releases
HOUSTON, March 19, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Mar 12, 2024 | Press Releases
Live webcast fireside chat on Monday, March 18th at 9:00 AM PT HOUSTON, March 12, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat...
by barry101 | Jan 24, 2024 | Press Releases
– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment – MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54% (N=13)...
by barry101 | Dec 20, 2023 | Press Releases
HOUSTON, Dec. 20, 2023 — Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a...
by barry101 | Dec 11, 2023 | Press Releases
– CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability – CR rate of 44% in subjects treated with Annamycin (n=9) – Durability of CR’s up to 8 months & climbing (no relapses to date) – Recruitment in MB-106 Phase...
by barry101 | Nov 13, 2023 | Press Releases
– MB-106: CR rate of 38% (N=8) with durability up to 8 months – Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15)...
